Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $26.4M | $25.2M | $20.7M | $48.8M | $17.8M | $157M | $271M | $331M | $451M | $875M |
| Revenue growth | — | -4.4% | -18.0% | 136.5% | -63.5% | 782.4% | 72.3% | 22.4% | 36.0% | 94.1% |
| Operating income | -$48.6M | -$57.4M | -$94.2M | -$99.5M | -$175M | -$178M | -$148M | -$104M | -$2.54M | $341M |
| Operating margin | -184.4% | -227.9% | -456.2% | -203.7% | -981.1% | -113.1% | -54.8% | -31.3% | -0.6% | 39.0% |
| Net income | -$55.1M | -$65.8M | -$101M | -$109M | -$183M | -$184M | -$247M | -$227M | -$88.9M | $264M |
| Net margin | -209.3% | -261.2% | -490.3% | -223.0% | -1026.4% | -117.1% | -91.2% | -68.4% | -19.7% | 30.2% |
| EPS (diluted) | -$0.75 | -$0.78 | -$0.98 | -$940.00 | -$1.09 | -$1.03 | -$1.33 | -$1.18 | -$0.43 | $1.21 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$53.4M | -$41.1M | -$92.6M | -$89.6M | -$135M | -$142M | -$162M | -$95.1M | -$52.0M | $347M |
| Capital expenditures | $5.28M | $328K | $366K | $343K | $514K | $2.38M | $1.35M | $2.17M | $1.12M | $2.47M |
| Free cash flow | -$58.7M | -$41.5M | -$92.9M | -$89.9M | -$136M | -$145M | -$163M | -$97.3M | -$53.1M | $345M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $22.1M | $50.3M | $26.7M | $114M | $272M | $504M | $305M | $111M | $105M | $89.7M |
| Total assets | $89.8M | $178M | $147M | $175M | $335M | $588M | $550M | $517M | $490M | $514M |
| Total liabilities | — | — | — | — | — | — | — | $972M | $966M | $633M |
| Long-term debt | $23.0M | $23.0M | $30.0M | $0.00 | $120M | $136M | $232M | $303M | $315M | $0.00 |
| Shareholders' equity | $1.58M | $83.8M | $49.2M | $38.3M | -$19.3M | -$107M | -$295M | -$456M | -$476M | -$119M |
| Retained earnings | -$566M | -$632M | -$732M | -$841M | -$1.02B | -$1.21B | -$1.45B | -$1.68B | -$1.77B | -$1.51B |
| Shares (wtd avg diluted) | 73.7M | 84.5M | 103M | 116M | 167M | 179M | 186M | 192M | 207M | 219M |
Every figure is extracted from BIOCRYST PHARMACEUTICALS INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.